Germany-based Bayer has launched Centafore, its Imaging Core Lab, to enhance imaging support for clinical trials and software as a medical device (SaMD) development.
Centafore, an Imaging Contract Research Organisation (iCRO), has been Bayer’s trusted partner for over 25 years, advancing the company’s drug pipeline.
The iCRO is now extending its expertise to external customers, delivering high-quality support for imaging studies and research initiatives across the industry.
Centafore offers personalised services to enhance the clients’ ability to manage imaging studies across diverse therapeutic areas and development phases.
It provides technology and image management, processing, interpretation services, expert project management and advanced imaging data analyses.
Centafore supports pharmaceutical, biotech, medical device, and digital health companies from early research through Phase 4 trials and SaMD development.
Its extensive network of experienced imaging professionals, including board-certified radiologists, enables effective study management in over 50 countries.
The services cater to a range of therapeutic areas such as cardiovascular, central nervous system (CNS), dermatology, digital health, oncology, paediatrics, and women’s health.
Also, the platform ensures compliance with regulatory and data privacy standards.
Furthermore, Centafore is collaborating with Luxsonic Technologies and OBIO to leverage clinical imaging as a key tool for enhanced decision-making in clinical trials and SaMD.
Bayer radiology president Nelson Ambrogio said: “Centafore represents a significant leap forward in our commitment to enhancing the landscape of clinical trial imaging and advancing the development of new medicines and healthcare solutions.
“By leveraging our extensive experience and expertise, we are dedicated to providing our customers with high-quality imaging services that meet their specific needs in clinical research.
“Through Centafore, we aim to enhance the reliability of trial outcomes and support informed decision-making in the development of investigational medicines, ultimately benefiting patients and improving their quality of care.”
